Platform for Plasmodium vivax vaccine discovery and development

Plasmodium vivax is the most prevalent malaria parasite on the American continent. It generates a global burden of 80-100 million cases annually and represents a tremendous public health problem, particularly in the American and Asian continents. A malaria vaccine would be considered the most cost-effective measure against this vector-borne disease and it would contribute to a reduction in malaria cases and to eventual eradication. Although significant progress has been achieved in the search for Plasmodium falciparum antigens that could be used in a vaccine, limited progress has been made in the search for P. vivax components that might be eligible for vaccine development. This is primarily due to the lack of in vitro cultures to serve as an antigen source and to inadequate funding. While the most advanced P. falciparum vaccine candidate is currently being tested in Phase III trials in Africa, the most advanced P. vivax candidates have only advanced to Phase I trials. Herein, we describe the overall strategy and progress in P. vivax vaccine research, from antigen discovery to preclinical and clinical development and we discuss the regional potential of Latin America to develop a comprehensive platform for vaccine development

WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys

The compound WR 238605 is a primaquine analog being developed by the U.S. Army as an antimalarial drug. Currently, there is no established treatment for Plasmodium vivax parasitemias that are not cured by chloroquine. This study tested WR 238605, chloroquine, and their combinations against a chloroquine-resistant strain of P. vivax (AMRU 1) in Aotus monkeys. A total dose of 3 mg/kg of WR 238605 given at a dosage of 1 mg/kg/day for three days cleared patent parasites in all eight monkeys but recrudescence of parasitemia occurred 15-25 days after initiation of treatment. A total dose of 9 mg/kg of WR 238605 over a three-day period cured all three monkeys of their infections. A total dose of 30 mg/kg of chloroquine did not clear patent infections in three monkeys, whereas a total dose of 60 mg/kg generally (two of three) cleared patent parasitemia but did not cure. Whereas total doses of 30 mg/kg of chloroquine or 3 mg/kg of WR 238605 given alone failed to cure, both drugs given in combination at these dosages cured two of three infections. These results indicate that WR 238605 may be an alternative treatment for chloroquine-resistant vivax malaria

The Infection Rates of Trypanosomes in Squirrel Monkeys at Two Sites in the Brazilian Amazon

A study was conducted to determine the prevalence of natural infections by trypanosome species in squirrel monkeys: Saimiri sciureus (Linnaeus) and Saimiri ustus (Geoffroy) caught respectively near 2 hydroelectric plants: Balbina, in the State of Amazonas, and Samuel, in the State of Rondônia, Brazil. A total of 165 squirrel monkeys were examined by thick and thin blood smears (BS), haemocultures and xenodiagnosis: 112 monkeys, 67.9%,(being 52.7% with mix infections) were positive to trypanosomes. Four species of trypanosomes were found in monkeys from the 2 areas: Trypanosoma (Tejeraia) rangeli Tejera or T. rangeli-like parasites in 58 squirrel monkeys (35.2%), Trypanosoma (Megatrypanum) minasense Chagas in 55 (33.3%), Trypanosoma (Herpetosoma) saimirii Rodhain or T. saimirii-like parasites in 53 (32.1%) and Trypanosoma (Schizotrypanum) cruzi Chagas in 17 (10.3%). As T. saimirii resembles T. minasense in blood-stream trypomastigotes and T. rangeli in cultural forms and in this survey almost all monkeys presenting trypanosomes morphologically indistinguishable from T. saimirii and/or T. minasense in BS were found through xenodiagnosis and/or haemoculture to be infected by T. rangeli, we suggest that the validity of T. saimirii needs to be evaluate